GSK plc
GLAXF · OTC
10/28/2025 | 9/30/2025 | 6/30/2025 | 3/31/2025 | |
|---|---|---|---|---|
| Market Cap | – | $63 | $55 | $62 |
| - Cash | – | $3 | $4 | $4 |
| + Debt | – | $18 | $0 | $18 |
| Enterprise Value | – | $77 | $52 | $76 |
| Revenue | $9 | – | $8 | $8 |
| % Growth | – | – | 6.3% | – |
| Gross Profit | $6 | – | $6 | $6 |
| % Margin | 73.6% | – | 72.9% | 74.2% |
| EBITDA | $3 | – | $3 | $3 |
| % Margin | 39.3% | – | 40.4% | 41.2% |
| Net Income | $2 | – | $1 | $2 |
| % Margin | 23.6% | – | 18.1% | 21.6% |
| EPS Diluted | 2.82 | – | 0.35 | 0.39 |
| % Growth | – | – | -10.3% | – |
| Operating Cash Flow | $3 | – | $2 | $1 |
| Capital Expenditures | -$0 | – | -$1 | -$0 |
| Free Cash Flow | $3 | – | $1 | $1 |